EXTL3

Across TCGA pan-cancer cohorts, EXTL3 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of EXTL3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where EXTL3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EXTL3 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

HNSC, LIHC, and COAD are the cancer types where EXTL3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EXTL3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+1.517	<.001	12	view →
LIHC	Female	II,III,IV	+1.297	<.001	9	view →
COAD	Female	All	+0.549	<.001	8	view →
THCA	Male	II,III,IV	−0.584	.001	7	view →
CHOL	Male	All	+2.178	<.001	5	view →
LUSC	Male	II,III,IV	+0.822	<.001	5	view →
LUAD	Male	II,III,IV	+0.597	.005	5	view →
BRCA	Female	All	−0.366	<.001	4	view →
KICH	All	All	−0.564	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

EXTL3–HNSC

Open the HNSC breakdown →